Background: Financial conflicts of interest (FCOIs) between the pharmaceutical industry and physicians have been associated with changes in prescribing behaviour, though the nature of this association in inflammatory bowel disease (IBD) is unknown. Aims: To investigate the relationship between the prescribing of biologic medications for IBD and industry payments to physicians from pharmaceutical companies making those medications. Methods: We used two US databases from 2013-2015: (1) The Centres for Medicare and Medicaid Services (CMS) Part D prescription claims database, which documents medications prescribed under Medicare; and (2) Dollars for Docs, which lists payments made by pharmaceutical companies to physicians. We identified physicians who prescribed biolgic medications for IBD and recorded industry payments physicians received from companies producing biologic medications in three categories: (1) Education; (2) Food and travel; and (3) other, such as speakers and consulting fees. A linear regression tested the association between payments received by a physician and dollar value of prescriptions written for biologics. A second regression was performed with an additional predictor variable to account for patient volume.
medications. These results highlight a potentially concerning influence of industry on prescribing behaviour.
Payments from pharmaceutical companies making biologic medications to physicians with 11 or more associated prescription claims for those biologic medications, from 2013-2015 inclusive Relationship between industry payments and prescriptions for biologic medications. Total payments received by each physician are plotted on horizontal axis, while total cost associated with prescriptions written by each physician is plotted on the vertical axis. Payments are only counted if they are made by a company producing a medication that the receiving physician prescribes.
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